Fosrolapitant and Palonosetron Hydrochloride is named as an intervention in 3 current clinical trials in our China register. 3 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Shanghai 6th People's Hospital (1). The most-studied condition is Chemotherapy-induced Nausea and Vomiting.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC
NCT07482891 · ClinicalTrials.gov ↗ · Chemotherapy-induced Nausea and Vomiting
|
Phase 4 | Recruiting | Shanghai 6th People's Hospital | China |
|
The Efficacy and Safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in Preventing Nausea and Vomiting Caused by Multi-cycle Immunotherapy and Chemotherapy in Patients With Esophageal Cancer and Lung Cancer
NCT07617246 · ClinicalTrials.gov ↗ · Esophagus Cancer, Lung Cancer
|
Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | China |
|
Fosrolapitant Combined With Palonosetron to Prevent Trastuzumab Rezetecan Related CINV
NCT07726433 · ClinicalTrials.gov ↗ · Chemotherapy-Induced Nausea and Vomiting (CINV)
|
Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Shanghai 6th People's Hospital | 1 |
| Tianjin Medical University Cancer Institute and Hospital | 1 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 3 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our China register name Fosrolapitant and Palonosetron Hydrochloride as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 3 trials are recruiting: 3 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Shanghai 6th People's Hospital (1), Tianjin Medical University Cancer Institute and Hospital (1) and Second Affiliated Hospital, Zhejiang University, School of Medicine (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Fosrolapitant and Palonosetron Hydrochloride works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Fosrolapitant and Palonosetron Hydrochloride works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Fosrolapitant and Palonosetron Hydrochloride (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.